Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies

Mitochondrion

Volumn 23, Issue , 2015, Pages 71-80

  Peralta, Susana ^a   Torraco, Alessandra ^b   Iommarini, Luisa ^c   Diaz, Francisca ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Mitochondria; Mitochondrial diseases; Mouse models; Oxidative phosphorylation; OXPHOS

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ALTERNATIVE OXIDASE; BEZAFIBRATE; CYCLOSPORIN A; FRATAXIN; MITOCHONDRIAL DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NICOTINAMIDE RIBOSIDE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RAPAMYCIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; MITOCHONDRIAL PROTEIN;

ADENOVIRIDAE; AOX GENE; CARDIOMYOPATHY; CELL PROLIFERATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CONTENT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EXERCISE; GENE; GENE DELETION; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HAPLOTYPE; HEART DISEASE; HUMAN; KETOGENIC DIET; LIPID DIET; METABOLIC BYPASS THERAPY; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL GENOME; MYOPATHY; ND4 GENE; NEUROPATHY; NONHUMAN; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; ANIMAL; DEFICIENCY; DIET; DISEASE MODEL; GENETICS; MITOCHONDRIAL DISEASES; MOUSE; ORGANELLE BIOGENESIS; PROCEDURES;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; GENETIC THERAPY; MICE; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; ORGANELLE BIOGENESIS; OXIDOREDUCTASES;

EID: 84937634662     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2015.01.007     Document Type: Review

References (86)

1. Agostino A., Valletta L., Chinnery P.F., Ferrari G., Carrara F., Taylor R.W., Schaefer A.M., Turnbull D.M., Tiranti V., Zeviani M. Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003, 60:1354-1356.
2. Ahlqvist K.J., Hämäläinen R.H., Yatsuga S., Uutela M., Terzioglu M., Götz A., Forsström S., Salven P., Angers-Loustau A., Kopra O.H., Tyynismaa H., Larsson N.G., Wartiovaara K., Prolla T., Trifunovic A., Suomalainen A. Somatic progenitor cell vulnerability to mitochondrial DNA mutagenesis underlies progeroid phenotypes in Polg mutator mice. Cell Metab. 2012, 15:100-109.
3. Ahola-Erkkilä S., Carroll C.J., Peltola-Mjösund K., Tulkki V., Mattila I., Seppänen-Laakso T., Oresic M., Tyynismaa H., Suomalainen A. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum. Mol. Genet. 2010, 19:1974-1984.
4. Akman H.O., Dorado B., Lopez L.C., Garcia-Cazorla A., Vila M.R., Tanabe L.M., Dauer W.T., Bonilla E., Tanji K., Hirano M. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum. Mol. Genet. 2008, 17:2433-2440.
5. Andreux P.A., Houtkooper R.H., Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat. Rev. Drug Discov. 2013, 12:465-483.
6. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
7. Bacman S.R., Williams S.L., Hernandez D., Moraes C.T. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther. 2007, 14:1309-1318.
8. Bacman S.R., Williams S.L., Garcia S., Moraes C.T. Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther. 2010, 17:713-720.
9. Bacman S.R., Williams S.L., Duan D., Moraes C.T. Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther. 2012, 19:1101-1106.
10. Bacman S.R., Williams S.L., Pinto M., Peralta S., Moraes C.T. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat. Med. 2013, 19:1111-1113.
11. Bai P., Canto C., Oudart H., Brunyanszki A., Cen Y., Thomas C., Yamamoto H., Huber A., Kiss B., Houtkooper R.H., Schoonjans K., Schreiber V., Sauve A.A., Menissier-de Murcia J., Auwerx J. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011, 13:461-468.
12. Bastin J., Aubey F., Rötig A., Munnich A., Djouadi F. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J. Clin. Endocrinol. Metab. 2008, 93:1433-1441.
13. Bayona-Bafaluy M.P., Blits B., Battersby B.J., Shoubridge E.A., Moraes C.T. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14392-14397.
14. Benton C.R., Wright D.C., Bonen A. PGC-1alpha-mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. Appl. Physiol. Nutr. Metab. 2008, 33:843-862.
15. Bonnefont J.P., Bastin J., Behin A., Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N. Engl. J. Med. 2009, 360:838-840.
16. Bottani E., Giordano C., Civiletto G., Di Meo I., Auricchio A., Ciusani E., Marchet S., Lamperti C., d'Amati G., Viscomi C., Zeviani M. AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure. Mol. Ther. 2014, 22:10-17.
17. Bouaita A., Augustin S., Lechauve C., Cwerman-Thibault H., Benit P., Simonutti M., Paques M., Rustin P., Sahel J.A., Corral-Debrinski M. Downregulation of apoptosis-inducing factor in Harlequin mice induces progressive and severe optic atrophy which is durably prevented by AAV2-AIF1 gene therapy. Brain 2012, 135:35-52.
18. Bundred N., Gardovskis J., Jaskiewicz J., Eglitis J., Paramonov V., McCormack P., Swaisland H., Cavallin M., Parry T., Carmichael J., Dixon J.M. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest. New Drugs 2013, 31:949-958.
19. Canto C., Houtkooper R.H., Pirinen E., Youn D.Y., Oosterveer M.H., Cen Y., Fernandez-Marcos P.J., Yamamoto H., Andreux P.A., Cettour-Rose P., Gademann K., Rinsch C., Schoonjans K., Sauve A.A., Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012, 15:838-847.
20. Cerutti R., Pirinen E., Lamperti C., Marchet S., Sauve A.A., Li W., Leoni V., Schon E.A., Dantzer F., Auwerx J., Viscomi C., Zeviani M. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 2014, 19:1042-1049.
21. Dai D.F., Chen T., Wanagat J., Laflamme M., Marcinek D.J., Emond M.J., Ngo C.P., Prolla T.A., Rabinovitch P.S. Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. Aging Cell 2010, 9:536-544.
22. Di Meo I., Auricchio A., Lamperti C., Burlina A., Viscomi C., Zeviani M. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol. Med. 2012, 4:1008-1014.
23. Dillon L.M., Hida A., Garcia S., Prolla T.A., Moraes C.T. Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse. PLoS One 2012, 7:e44335.
24. Dillon L.M., Williams S.L., Hida A., Peacock J.D., Prolla T.A., Lincoln J., Moraes C.T. Increased mitochondrial biogenesis in muscle improves aging phenotypes in the mtDNA mutator mouse. Hum. Mol. Genet. 2012, 21:2288-2297.
25. Djouadi F., Bastin J. Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders. Cell Metab. 2011, 14:715-716. (author reply 717).
26. El-Khoury R., Dufour E., Rak M., Ramanantsoa N., Grandchamp N., Csaba Z., Duvillie B., Benit P., Gallego J., Gressens P., Sarkis C., Jacobs H.T., Rustin P. Alternative oxidase expression in the mouse enables bypassing cytochrome c oxidase blockade and limits mitochondrial ROS overproduction. PLoS Genet. 2013, 9:e1003182.
27. El-Khoury R., Kemppainen K.K., Dufour E., Szibor M., Jacobs H.T., Rustin P. Engineering the alternative oxidase gene to better understand and counteract mitochondrial defects: state of the art and perspectives. Br. J. Pharmacol. 2014, 171:2243-2249.
28. Ellouze S., Augustin S., Bouaita A., Bonnet C., Simonutti M., Forster V., Picaud S., Sahel J.A., Corral-Debrinski M. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am. J. Hum. Genet. 2008, 83:373-387.
29. Fernandez-Ayala D.J., Sanz A., Vartiainen S., Kemppainen K.K., Babusiak M., Mustalahti E., Costa R., Tuomela T., Zeviani M., Chung J., O'Dell K.M., Rustin P., Jacobs H.T. Expression of the Ciona intestinalis alternative oxidase (AOX) in Drosophila complements defects in mitochondrial oxidative phosphorylation. Cell Metab. 2009, 9:449-460.
30. Flierl A., Chen Y., Coskun P.E., Samulski R.J., Wallace D.C. Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther. 2005, 12:570-578.
31. 2+ and AMP. Biochem. J. 2010, 426:109-118.
32. Garone C., Garcia-Diaz B., Emmanuele V., Lopez L.C., Tadesse S., Akman H.O., Tanji K., Quinzii C.M., Hirano M. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol. Med. 2014, 6:1016-1027.
33. Guy J., Qi X., Pallotti F., Schon E.A., Manfredi G., Carelli V., Martinuzzi A., Hauswirth W.W., Lewin A.S. Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann. Neurol. 2002, 52:534-542.
34. Handschin C., Spiegelman B.M. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 2006, 27:728-735.
35. Hirano M., Marti R., Spinazzola A., Nishino I., Nishigaki Y. Thymidine phosphorylase deficiency causes MNGIE: an autosomal recessive mitochondrial disorder. Nucleosides Nucleotides Nucleic Acids 2004, 23:1217-1225.
36. Hirano M., Garone C., Quinzii C.M. CoQ(10) deficiencies and MNGIE: two treatable mitochondrial disorders. Biochim. Biophys. Acta 2012, 1820:625-631.
37. Houtkooper R.H., Pirinen E., Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 2012, 13:225-238.
38. Jager S., Handschin C., St-Pierre J., Spiegelman B.M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12017-12022.
39. Jenuth J.P., Peterson A.C., Shoubridge E.A. Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice. Nat. Genet. 1997, 16:93-95.
40. Johnson S.C., Rabinovitch P.S., Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature 2013, 493:338-345.
41. Johnson S.C., Yanos M.E., Kayser E.B., Quintana A., Sangesland M., Castanza A., Uhde L., Hui J., Wall V.Z., Gagnidze A., Oh K., Wasko B.M., Ramos F.J., Palmiter R.D., Rabinovitch P.S., Morgan P.G., Sedensky M.M., Kaeberlein M. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science 2013, 342:1524-1528.
42. Kakizaki Y., Seymour R.S., Ito K. A novel functional element in the N-terminal region of Arum concinnatum alternative oxidase is indispensable for catalytic activity of the enzyme in HeLa cells. Biochim. Biophys. Acta 2010, 1797:20-28.
43. Kawamata H., Tiranti V., Magrané J., Chinopoulos C., Manfredi G. adPEO mutations in ANT1 impair ADP-ATP translocation in muscle mitochondria. Hum. Mol. Genet. 2011, 20:2964-2974.
44. Khan N.A., Auranen M., Paetau I., Pirinen E., Euro L., Forsstrom S., Pasila L., Velagapudi V., Carroll C.J., Auwerx J., Suomalainen A. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol. Med. 2014, 6:721-731.
45. Kujoth G.C., Hiona A., Pugh T.D., Someya S., Panzer K., Wohlgemuth S.E., Hofer T., Seo A.Y., Sullivan R., Jobling W.A., Morrow J.D., Van Remmen H., Sedivy J.M., Yamasoba T., Tanokura M., Weindruch R., Leeuwenburgh C., Prolla T.A. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 2005, 309:481-484.
46. Lopez L.C., Akman H.O., Garcia-Cazorla A., Dorado B., Marti R., Nishino I., Tadesse S., Pizzorno G., Shungu D., Bonilla E., Tanji K., Hirano M. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Hum. Mol. Genet. 2009, 18:714-722.
47. Mott J.L., Zhang D., Freeman J.C., Mikolajczak P., Chang S.W., Zassenhaus H.P. Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A. Biochem. Biophys. Res. Commun. 2004, 319:1210-1215.
48. Murphy J.L., Blakely E.L., Schaefer A.M., He L., Wyrick P., Haller R.G., Taylor R.W., Turnbull D.M., Taivassalo T. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008, 131:2832-2840.
49. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., Evans R.M. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008, 134:405-415.
50. Noe N., Dillon L., Lellek V., Diaz F., Hida A., Moraes C.T., Wenz T. Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion 2013, 13:417-426.
51. Ojuka E.O. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc. Nutr. Soc. 2004, 63:275-278.
52. Perales-Clemente E., Fernández-Silva P., Acín-Pérez R., Pérez-Martos A., Enríquez J.A. Allotopic expression of mitochondrial-encoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task?. Nucleic Acids Res. 2011, 39:225-234.
53. Perdomini M., Belbellaa B., Monassier L., Reutenauer L., Messaddeq N., Cartier N., Crystal R.G., Aubourg P., Puccio H. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat. Med. 2014, 20:542-547.
54. Pfeffer G., Horvath R., Klopstock T., Mootha V.K., Suomalainen A., Koene S., Hirano M., Zeviani M., Bindoff L.A., Yu-Wai-Man P., Hanna M., Carelli V., McFarland R., Majamaa K., Turnbull D.M., Smeitink J., Chinnery P.F. New treatments for mitochondrial disease-no time to drop our standards. Nat. Rev. Neurol. 2013, 9:474-481.
55. Pirinen E., Canto C., Jo Y.S., Morato L., Zhang H., Menzies K.J., Williams E.G., Mouchiroud L., Moullan N., Hagberg C., Li W., Timmers S., Imhof R., Verbeek J., Pujol A., van Loon B., Viscomi C., Zeviani M., Schrauwen P., Sauve A.A., Schoonjans K., Auwerx J. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 2014, 19:1034-1041.
56. Quintana A., Kruse S.E., Kapur R.P., Sanz E., Palmiter R.D. Complex I deficiency due to loss of Ndufs4 in the brain results in progressive encephalopathy resembling Leigh syndrome. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10996-11001.
57. Quintana A., Zanella S., Koch H., Kruse S.E., Lee D., Ramirez J.M., Palmiter R.D. Fatal breathing dysfunction in a mouse model of Leigh syndrome. J. Clin. Invest. 2012, 122:2359-2368.
58. Rossmanith W., Freilinger M., Roka J., Raffelsberger T., Moser-Thier K., Prayer D., Bernert G., Bittner R.E. Isolated cytochrome c oxidase deficiency as a cause of MELAS. J. Med. Genet. 2008, 45:117-121.
59. Saada A. The use of individual patient's fibroblasts in the search for personalized treatment of nuclear encoded OXPHOS diseases. Mol. Genet. Metab. 2011, 104:39-47.
60. Safdar A., Bourgeois J.M., Ogborn D.I., Little J.P., Hettinga B.P., Akhtar M., Thompson J.E., Melov S., Mocellin N.J., Kujoth G.C., Prolla T.A., Tarnopolsky M.A. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4135-4140.
61. Sandi C., Pinto R.M., Al-Mahdawi S., Ezzatizadeh V., Barnes G., Jones S., Rusche J.R., Gottesfeld J.M., Pook M.A. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis. 2011, 42:496-505.
62. Santra S., Gilkerson R.W., Davidson M., Schon E.A. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann. Neurol. 2004, 56:662-669.
63. Scarpulla R.C. Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator. Ann. N. Y. Acad. Sci. 2008, 1147:321-334.
64. Schaefer A.M., Taylor R.W., Turnbull D.M., Chinnery P.F. The epidemiology of mitochondrial disorders-past, present and future. Biochim. Biophys. Acta 2004, 1659:115-120.
65. Schiff M., Benit P., El-Khoury R., Schlemmer D., Benoist J.F., Rustin P. Mouse studies to shape clinical trials for mitochondrial diseases: high fat diet in Harlequin mice. PLoS One 2011, 6:e28823.
66. Schleit J., Johnson S.C., Bennett C.F., Simko M., Trongtham N., Castanza A., Hsieh E.J., Moller R.M., Wasko B.M., Delaney J.R., Sutphin G.L., Carr D., Murakami C.J., Tocchi A., Xian B., Chen W., Yu T., Goswami S., Higgins S., Holmberg M., Jeong K.S., Kim J.R., Klum S., Liao E., Lin M.S., Lo W., Miller H., Olsen B., Peng Z.J., Pollard T., Pradeep P., Pruett D., Rai D., Ros V., Singh M., Spector B.L., Vander Wende H., An E.H., Fletcher M., Jelic M., Rabinovitch P.S., MacCoss M.J., Han J.D., Kennedy B.K., Kaeberlein M. Molecular mechanisms underlying genotype-dependent responses to dietary restriction. Aging Cell 2013, 12:1050-1061.
67. Schon E.A., DiMauro S., Hirano M., Gilkerson R.W. Therapeutic prospects for mitochondrial disease. Trends Mol. Med. 2010, 16:268-276.
68. Schon E.A., DiMauro S., Hirano M. Human mitochondrial DNA: roles of inherited and somatic mutations. Nat. Rev. Genet. 2012, 13:878-890.
69. Srivastava S., Diaz F., Iommarini L., Aure K., Lombes A., Moraes C.T. PGC-1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum. Mol. Genet. 2009, 18:1805-1812.
70. Taivassalo T., Shoubridge E.A., Chen J., Kennaway N.G., DiMauro S., Arnold D.L., Haller R.G. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann. Neurol. 2001, 50:133-141.
71. Taivassalo T., Gardner J.L., Taylor R.W., Schaefer A.M., Newman J., Barron M.J., Haller R.G., Turnbull D.M. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain 2006, 129:3391-3401.
72. Tenenbaum A., Motro M., Fisman E.Z., Tanne D., Boyko V., Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 2005, 165:1154-1160.
73. Thorburn D.R., Dahl H.H. Mitochondrial disorders: genetics, counseling, prenatal diagnosis and reproductive options. Am. J. Med. Genet. 2001, 106:102-114.
74. Torres-Torronteras J., Gomez A., Eixarch H., Palenzuela L., Pizzorno G., Hirano M., Andreu A.L., Barquinero J., Marti R. Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther. 2011, 18:795-806.
75. Torres-Torronteras J., Viscomi C., Cabrera-Perez R., Camara Y., Di Meo I., Barquinero J., Auricchio A., Pizzorno G., Hirano M., Zeviani M., Marti R. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Mol. Ther. 2014, 22:901-907.
76. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly Y.M., Gidlof S., Oldfors A., Wibom R., Tornell J., Jacobs H.T., Larsson N.G. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004, 429:417-423.
77. Tyynismaa H., Mjosund K.P., Wanrooij S., Lappalainen I., Ylikallio E., Jalanko A., Spelbrink J.N., Paetau A., Suomalainen A. Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17687-17692.
78. Viscomi C., Bottani E., Civiletto G., Cerutti R., Moggio M., Fagiolari G., Schon E.A., Lamperti C., Zeviani M. In vivo correction of COX deficiency by activation of the AMPK/PGC-1α axis. Cell Metab. 2011, 14:80-90.
79. Wallace D.C., Fan W., Procaccio V. Mitochondrial energetics and therapeutics. Annu. Rev. Pathol. 2010, 5:297-348.
80. Wenz T., Diaz F., Spiegelman B.M., Moraes C.T. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008, 8:249-256.
81. Wenz T., Rossi S.G., Rotundo R.L., Spiegelman B.M., Moraes C.T. Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20405-20410.
82. Williams S.L., Huang J., Edwards Y.J., Ulloa R.H., Dillon L.M., Prolla T.A., Vance J.M., Moraes C.T., Zuchner S. The mtDNA mutation spectrum of the progeroid Polg mutator mouse includes abundant control region multimers. Cell Metab. 2010, 12:675-682.
83. Wu H., Kanatous S.B., Thurmond F.A., Gallardo T., Isotani E., Bassel-Duby R., Williams R.S. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002, 296:349-352.
84. Yatsuga S., Suomalainen A. Effect of bezafibrate treatment on late-onset mitochondrial myopathy in mice. Hum. Mol. Genet. 2012, 21:526-535.
85. Yu H., Koilkonda R.D., Chou T.H., Porciatti V., Ozdemir S.S., Chiodo V., Boye S.L., Boye S.E., Hauswirth W.W., Lewin A.S., Guy J. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber's hereditary optic neuropathy in a mouse model. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1238-E1247.
86. Zeviani M., Di Donato S. Mitochondrial disorders. Brain 2004, 127:2153-2172.